NCT05594615View on ClinicalTrials.gov

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

November 4, 2022

Study Completion Date

November 18, 2022

Conditions
COVID-19
Interventions
DRUG

EDP-235

Subjects will receive EDP-235 once daily on Days 5-15

DRUG

Midazolam

Subjects will receive midazolam once daily on Days 1 and 12

DRUG

Rosuvastatin

Subjects will receive rosuvastatin once daily on Days 2 and 13

DRUG

Caffeine

Subjects will receive caffeine once daily on Days 1 and 12

Trial Locations (1)

84124

ICON, plc., Salt Lake City

Sponsors
All Listed Sponsors
lead

Enanta Pharmaceuticals, Inc

INDUSTRY

NCT05594615 - Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects | Biotech Hunter | Biotech Hunter